Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: HRA Pharma Clear all
Completed No phase listed Observational Accepts healthy volunteers

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

NCT01107106
View directory record Official record
Conditions
Contraception
Interventions
ellaOne® (ulipristal acetate)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Denver, Colorado • Lakewood, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

NCT00551616
View directory record Official record
Conditions
Contraception
Interventions
CDB-2914, Levonorgestrel
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
16 Years and older · Female only
Enrollment
2,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Oral Contraception Under Simulated OTC Conditions

NCT03559010
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg tablets
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
44
States / cities
Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 28, 2026, 10:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

NCT01569737
View directory record Official record
Conditions
Emergency Contraception
Interventions
ella
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

NCT03585712
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Sacramento, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

NCT03208985
View directory record Official record
Conditions
Emergency Contraception
Interventions
Use Phase (Ulipristal Acetate, 30 mg)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
34
States / cities
Rancho Cucamonga, California • Boulder, Colorado • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CDB-2914 for Emergency Contraception

NCT00411684
View directory record Official record
Conditions
Emergency Contraception
Interventions
CDB-2914
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
17
States / cities
San Jose, California • Denver, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

NCT04112095
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg tablets
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
11 Years and older · Female only
Enrollment
962 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
38
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

NCT00290251
View directory record Official record
Conditions
Leiomyoma
Interventions
ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 28, 2026, 10:11 AM EDT